Castleark Management’s Aerie Pharmaceuticals AERI Stock Holding History

Castleark Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-58,125	Closed	-$3.58M	–	410
2018 Q3	$3.58M	Buy	+58,125	New	+$3.74M	0.1%	217
2018 Q1	–	Sell	-45,223	Closed	-$2.7M	–	448
2017 Q4	$2.7M	Sell	45,223 -86,895	-66%	-$5.27M	0.08%	239
2017 Q3	$6.42M	Buy	132,118 +54,580	+70%	+$2.98M	0.2%	157
2017 Q2	$4.08M	Buy	77,538 +19,648	+34%	+$915K	0.13%	201
2017 Q1	$2.63M	Buy	+57,890	New	+$2.58M	0.08%	255

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Castleark Management's AERI Position: Q4 2018 in Review

Castleark Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 58,125 shares — an estimated $3.58M sold.

Castleark Management first reported a position in AERI in Q1 2017 and held it in 5 quarters. The position peaked at $6.42M in Q3 2017. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Castleark Management reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Castleark Management sold 58,125 Aerie Pharmaceuticals shares in Q4 2018, an estimated $3.58M.
Castleark Management first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Castleark Management's Aerie Pharmaceuticals position peaked at $6.42M in Q3 2017.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Castleark Management's 13F filing for Q4 2018, filed 12 Feb 2019.